Are Peptides Illegal in the US? Compounding, Imports, and HGH

Peptides are not broadly illegal in the US, but the FDA treats most of them as drugs, and that classification decides whether any particular transaction is lawful. A peptide with FDA approval and a valid prescription is legal. A peptide sold online for self-injection, imported from an overseas vendor, or marketed with health claims outside the approval system is not. The rules tightened sharply in 2025, cutting off compounded and unapproved sources that many people had been relying on.

Why the Molecule Isn’t the Point

Under the Federal Food, Drug, and Cosmetic Act, the FDA regulates peptides as drugs unless a narrow exception applies.¹ Any peptide product sold with claims about treating, preventing, or curing a medical condition is legally a drug no matter what the label says.²

Federal law then prohibits introducing unapproved, adulterated, or misbranded drugs into interstate commerce.³ So the legal question isn’t whether a peptide molecule is banned. It’s whether the peptide has FDA approval, whether it’s being sold or shipped for human use, and whether a licensed prescriber is in the picture.

Peptides That Are Legal With a Prescription

Dozens of peptide-based drugs have completed FDA approval and are fully legal when prescribed by a licensed provider and dispensed by a licensed pharmacy. Semaglutide is the most visible example. As Ozempic it’s approved for type 2 diabetes,⁴ and as Wegovy it’s approved for chronic weight management and cardiovascular risk reduction in adults with obesity or overweight.⁵ Insulin, oxytocin, and octreotide are other examples of approved peptide drugs used routinely in clinical care.

The pattern is the same across all of them: prescription, licensed pharmacy, approved indication. Step outside any of those three and the same molecule becomes a legal problem.

Compounded Peptides After the 2025 Shortage Ruling

Compounding pharmacies can legally prepare customized medications under Sections 503A and 503B of the FD&C Act, but they generally cannot make drugs that are “essentially copies” of commercially available FDA-approved products.⁶ While semaglutide and tirzepatide sat on the FDA’s drug shortage list in 2022–2024, that copy restriction was suspended, and millions of patients got compounded GLP-1s through licensed pharmacies at lower cost.

That window closed. On February 21, 2025, the FDA declared the semaglutide injection shortage resolved and set wind-down dates for compounders, with 503A pharmacies given until April 22, 2025 and 503B outsourcing facilities until May 22, 2025.⁷ After those dates, compounding semaglutide fell back under the standard prohibition on copying an approved drug. The agency also launched a “green list” import alert that lets customs detain shipments of GLP-1 active ingredients from unverified foreign manufacturers without physical examination.⁸ If your compounded semaglutide supply disappeared in 2025, this is why.

Peptides the FDA Has Banned From Compounding

Beyond the GLP-1 changes, the FDA placed several popular peptides on its “Category 2” list in September 2023, meaning licensed pharmacies cannot compound them at all. The agency cited some combination of missing human safety data, immunogenicity concerns, or reports of serious adverse events for each substance on the list.⁹

BPC-157, marketed for gut healing and injury recovery, flagged for immunogenicity risks and near-total lack of human safety data.
Ipamorelin acetate, linked in one study to serious adverse events including death when given intravenously.
Melanotan II, associated in case reports with melanoma and other serious conditions.
GHRP-2 and GHRP-6, tied to adverse events including pancreatitis and blood sugar disruption.
Cathelicidin LL-37, flagged in nonclinical research for possible tumor-promoting effects.
Dihexa acetate, Epitalon, KPV, and PEG-MGF, all with no meaningful human exposure data.

Any pharmacy or clinic still selling these for human use is operating outside the law.

“Research Only” Peptides Sold Online

A large online market sells peptides with labels reading “for research purposes only” or “not for human consumption.” Sellers treat that phrase as a legal shield; the FDA does not. In a February 2025 warning letter to USApeptide.com, the agency stated that despite the research-only disclaimers, evidence from the website established the products were drugs intended for human use, and cited the company for introducing misbranded and unapproved drugs into interstate commerce.¹⁰

The FDA looks at marketing context: dosage guidance, testimonials, before-and-after content, or any language about human health benefits makes the disclaimer legally meaningless. Selling without a prescription also makes the product misbranded, because these are prescription-level drugs that can’t carry adequate directions for lay use.¹⁰

For individual buyers, the exposure is lower than for sellers but not zero. Federal law does not carve out a clean personal-use exception for unapproved drugs. Customs routinely seizes these shipments, and a buyer whose package is intercepted typically receives a seizure notice with the option to petition for return or forfeit the items. Most people forfeit, because contesting the seizure draws more attention than the shipment is worth.

Importing Peptides From Overseas

The FDA’s stated position is that in most circumstances, importing unapproved drugs into the United States is illegal, even for personal use. The agency exercises limited enforcement discretion only when the drug treats a serious condition with no domestic option, the product doesn’t pose an unreasonable risk, the quantity is no more than a three-month supply, and the consumer names a U.S.-licensed doctor overseeing their care.¹¹

Research-chemical peptides ordered from overseas vendors don’t meet any of those conditions. Customs and Border Protection seizes the shipments under both customs law and the FD&C Act, and the green list import alert added another interception tool for GLP-1 ingredients specifically.⁸

Human Growth Hormone Sits Under Its Own Statute

HGH isn’t a controlled substance, but Congress wrote separate restrictions for it into the 1990 Anabolic Steroids Control Act. Distributing HGH for any use other than treatment of a disease or recognized medical condition, authorized by the Secretary of Health and Human Services and prescribed by a physician, is a federal felony carrying up to five years in prison.¹² Prescribing HGH for anti-aging, bodybuilding, or general performance enhancement is illegal even when a licensed doctor signs the script. Growth hormone releasing peptides such as GHRP-2 and GHRP-6 don’t sit under this statute, but they face the same FD&C Act restrictions as other unapproved drugs when sold for human use.

Penalties for Selling or Distributing

Under the FD&C Act, a first offense for selling or distributing unapproved or misbranded drugs carries up to one year in prison, a fine of up to $1,000, or both. With intent to defraud or mislead, or with a prior conviction, the penalties rise to up to three years in prison and a fine of up to $10,000.¹³

Prosecuted cases can involve much larger numbers. A New Jersey couple who admitted to selling misbranded and unapproved drugs including peptides were required to forfeit more than $3 million in criminal proceeds, and the underlying conspiracy charge carried a potential fine of up to $250,000 or twice the gross gain, whichever was greater.¹⁴

Providers face professional consequences on top of criminal exposure. State medical boards can impose fines, suspension, or revocation for prescribing or recommending unapproved drugs, and malpractice insurance is unlikely to cover claims arising from treatment that falls outside the accepted standard of care.

Athletes Face an Extra Layer

Athletes under anti-doping rules are subject to prohibitions that go beyond FDA classification. The World Anti-Doping Agency’s Prohibited List bans peptide hormones, growth factors, and related substances under category S2, and any peptide that hasn’t received regulatory approval for human use anywhere in the world is separately banned under category S0. USADA has confirmed BPC-157 is prohibited under S0, and violations can produce suspensions ranging from months to years along with loss of results.¹⁵ Athletes competing under WADA, NCAA, or professional-league programs should assume that essentially all non-prescribed peptide products are prohibited.

1
Food and Drug Administration. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin
2
U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements
3
Office of the Law Revision Counsel. 21 US Code 331 – Prohibited Acts
4
Food and Drug Administration. OZEMPIC (Semaglutide) Injection Label
5
U.S. Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
6
U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
7
Food and Drug Administration. Declaratory Order – Resolution of Shortages of Semaglutide Injection
8
U.S. Food and Drug Administration. FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients
9
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
10
United States Food and Drug Administration. USApeptide.com – 696885 – 02/26/2025
11
U.S. Food and Drug Administration. Personal Importation
12
DEA Diversion Control Division. Human Growth Hormone
13
Office of the Law Revision Counsel. 21 USC 333 – Penalties
14
United States Department of Justice. New Jersey Husband and Wife Admit Selling Misbranded and Unapproved New Drugs
15
USADA. BPC-157 Experimental Peptide Creates Risk for Athletes